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Background: A detailed analysis of whole genomes can be now achieved with next generation sequencing.
Epstein Barr Virus (EBV) transformation is a widely used strategy in clinical research to obtain an unlimited source of
a subject’s DNA. Although the mechanism of transformation and immortalization by EBV is relatively well known at
the transcriptional and proteomic level, the genetic consequences of EBV transformation are less well understood. A
detailed analysis of the genetic alterations introduced by EBV transformation is highly relevant, as it will inform on
the usefulness and limitations of this approach.
Results: We used whole genome sequencing to assess the genomic signature of a low-passage lymphoblastoid
cell line (LCL). Specifically, we sequenced the full genome (40X) of an individual using DNA purified from fresh
whole blood as well as DNA from his LCL. A total of 217.33 Gb of sequence were generated from the cell line and
238.95 Gb from the normal genomic DNA. We determined with high confidence that 99.2% of the genomes were
identical, with no reproducible changes in structural variation (chromosomal rearrangements and copy number
variations) or insertion/deletion polymorphisms (indels).
Conclusions: Our results suggest that, at this level of resolution, the LCL is genetically indistinguishable from its
genomic counterpart and therefore their use in clinical research is not likely to introduce a significant bias.
Keywords: Next generation sequencing, EBV transformation, Lymphoblastoid cell line, GeneticsBackground
Epstein-Barr virus (EBV) is a herpesvirus that infects
epithelial and B cells and has been associated with the
development of various tumors, including Hodgkin’s and
Burkitt’s lymphoma [1-4]. Since EBV is able to transform
B cells into continuously proliferating lymphoblastoid
cell lines (LCLs), it is commonly used as a tool in clinical
research for creating an unlimited source of patients’
material [5-9]. Although LCLs have been used frequently
as a source of DNA in genetic studies, controversy still
exists about their reliability in faithfully replicating the
variation present in the donor germ-line (e.g. [6,9-13]).* Correspondence: sebaran@cgl.ucsf.edu
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reproduction in any medium, provided the orIn all latently infected LCLs, the EBV genome is
present in the form of extra-chromosomal copies (epi-
somes) from which the viral genome is replicated [4].
Most research on the transforming abilities of EBV has
been focused on the expression of viral gene products
and the host’s transcriptional response. From this body
of research it is now well understood that the viral tran-
scription factor EBV nuclear antigen (EBNA)-2 activates
the expression of several EBV proteins and non-coding
RNAs - the growth transcription program - that inter-
fere with the host’s signaling pathways [2,14]. Specific-
ally, the growth transcription program drives cell
transformation by activating cellular proliferation, while
suppressing growth inhibitors [14]. Even though the viral
gene products exert their transforming functions primar-
ily by interacting with host proteins, recent evidence
suggests that EBV also promotes genomic instability inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cause mutations through integration and disintegration
into the host’s genome (e.g. [16,17]). These putative early
(pre-immortal) genetic consequences of EBV infection
are less well studied. If ascertained, those structural gen-
omic changes would have important implications for the
interpretation of a large number of genetic studies that
assume LCLs are a bona-fide source of genomic DNA.
In recent years, massively parallel DNA (i.e. next gen-
eration) sequencing has become increasingly affordable
[18], enabling the discovery of causative DNA variants in
rare genetic diseases [19-21] and providing new insights
into carcinogenesis and autoimmunity [22-32]. A recent
study reported the comparison of DNA isolated from
peripheral lymphocytes and from an LCL from the same
individuals by means of exome sequencing [33]. This
study concluded that the exome fractions of genomic
and lymphoblastoid cell line DNA (roughly 1-2% of the
genomes) are more than 99% identical.
Whole genome sequencing can, in addition to identify-
ing variation in coding regions, reveal copy number vari-
ation (CNV) and chromosomal rearrangements at high
resolution. A whole genome sequence data set is there-
fore multilayered and can be queried for different
aspects of genomic organization, making it a valuable
tool for our study. Here we report the analysis of
complete genome sequencing (40X) of a single individ-
ual to gain a better understanding of putative genetic
alterations introduced by EBV transformation.
Results
Here we report the complete sequencing and analysis of
the normal genomic and lymphoblastoid cell line DNA
from the same individual. We organized our analysis so as
to proceed from investigation of major chromosomal rear-
rangements to small sequence variation, to single base
changes. As a preliminary step, we performed high reso-
lution karyotyping of the cell line to identify major chromo-
somal abnormalities. Fifteen out of 20 analyzed metaphases
showed a normal karyotype (Additional file 1). Only 5 cells
showed random changes in chromosome number, consist-
ent with what would be expected for an early-passage LCL.
Once sequencing data was obtained, we evaluated quality
metrics of the two sequencing data sets, such as overall
coverage, ratio of hetero-to-homozygous single nucleotide
polymorphisms (SNPs) and the ratio of SNP transitions
to transversions. These parameters are similar to those
reported for previously sequenced genomes using the same
technology (e.g. [20,21,34]) and other human datasets using
next generation sequencing (Additional file 2). We also
assessed the presence of viral DNA. To this end, we
extracted raw reads of sequences that did not map to the
human genome and aligned these to the EBV genome. We
found an average of 2 copies of EBV DNA reads in the cellline as compared to 0 copies in the genomic DNA (data
not shown), confirming that viral DNA was present only in
the cell line sample. Since EBV has been described to
integrate into host DNA (e.g. [35-40]), we also
checked for viral DNA in all longer (>8 nt) insertions
and substitutions that passed a pre-determined quality
filter (SomaticScore of at least 0.1), as well as in all
“non-reference” DNA stretches joining the two arms
of a chromosomal rearrangement in the cell line
(transition sequences). None of these calls supported
the presence of inserted EBV genomic information.
A total of 217.33 Gb of sequence were generated from
the cell line and 238.95 Gb from the genomic DNA. This
difference in coverage did not alter most of the para-
meters analyzed, as these were highly similar between
the two genomes (Table 1). While the slightly deeper
coverage of the genomic DNA did result in more var-
iants being called in this sample, the overall depth of
coverage was highly similar for the two genomes (~ 80%
of both genomes were covered at least 40 times,
Figure 1A and C). Also, the regional distribution of reads
was highly concordant (Figure 1B). Once we established
that quality measures were not significantly different, we
set out to make a detailed comparison between the two
genomes.
First, we assessed whether the two genomes differed in
structural variants, i.e. chromosomal rearrangements and
copy number variations (CNVs). Chromosomal rearrange-
ments can be inferred from reads spanning over a stretch
of DNA that is not contiguous in the reference genome
(discordant reads). For example, if one half of a sequence
read maps to chromosome 1 and the other half to
chromosome 3, this might be indicative of a translocation
event. By visual inspection of reported DNA junctions, we
found that both genomes exhibited a largely similar num-
ber of chromosomal rearrangements compared to the
reference and that they shared most of the inter-
chromosomal junctions as well (Figure 2A). Indeed, a
similar but small number of unique chromosomal rear-
rangements were identified in each genome (131 in gen-
omic, 78 in cell line; see Additional files 3, 4. 5); 34% and
45% of these unique junctions, respectively, had been
detected in more than 75% of all other genomes
sequenced by CGI at that time and hence might represent
false positives (Additional files 4 and 5). To examine
whether observed junctions might be linked to the trans-
formation process, we reasoned that if the observed dif-
ferences were of biological origin (e.g. driven by the trans-
formation), a set of genes involved in cell cycle regulation
would be among the affected loci. GO and KEGG analyses
revealed very similar gene categories affected by chromo-
somal rearrangements in both genomes (data not shown),
thus suggesting these differences were likely random or
false discoveries.
Table 1 Quality metrics of the sequenced genomes
genomic cell line
Gender male male
Gross mapping yield (Gb) 238.95 217.33
SNP Transitions/transversions 2.14076 2.1468
SNP het/hom ratio 1.582496107 1.571157051
INS het/hom ratio 1.344223031 1.289809921
DEL het/hom ratio 1.663654705 1.654600015
SUB het/hom ratio 1.715782613 1.713757678
SNP total count 3346813 3271797
INS total count 187392 170265
DEL total count 204807 186626
SUB total count 71344 66370
SNP novel rate 0.0487541 0.0472266
INS novel rate 0.189213 0.17794
DEL novel rate 0.239469 0.235096
SUB novel rate 0.309865 0.295857
Fully called genome fraction 0.967831529 0.961877785
Partially called genome fraction 0.004574129 0.006604011
No-called genome fraction 0.027594342 0.031518204
Synonymous SNP loci 9778 9387
Missense SNP loci 9329 8935
Nonsense SNP loci 90 89
Nonstop SNP loci 13 13
Frame-shifting INS loci 121 110
Frame-shifting DEL loci 108 100
Frame-shifting SUB loci 17 13
Frame-preserving INS loci 113 101
Frame-preserving DEL loci 107 91
Frame-preserving SUB loci 258 227
Frame-shifting/preserving ratio 0.514644351 0.53221957
Nonsyn/syn SNP ratio 0.954080589 0.951848301
Insertion/deletions ratio 0.914968727 0.912332687
Ins + del/SNP ratio 0.117185812 0.109081034
Coding insertion/deletions ratio 1.060465116 1.078534031
Coding SNP/all SNP ratio 0.00626387 0.006151054
Coding (ins + del)/all (ins + del) ratio 0.001129529 0.001112384
This table also lists information on the number and kind of indels identified
per genome, but does not contain data on structural variances.
Gb: gigabase, SNP: single nucleotide polymorphism, INS: insertion, DEL:
deletion, SUB: substitution, (Non)syn: (non-)synonymous.
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from genome coverage files in windows of 2 kb
(Figure 2B). Both genomes shared almost all CNVs
throughout the genome; of note, most DNA stretches with
ploidy > 2 were observed near telomers and centromers,
likely reflecting the difficulty to properly align reads in
these highly repetitive DNA regions. The cell line showeda decreased copy number in only 4 regions (3 haploid
regions, one deletion) as compared to the genomic DNA
(Additional file 6). Four genes (KIAA0125, PRAME,
ZNF280A, ZNF280B) and one pseudogene (ADAM6)
were affected by the CNVs (Additional file 6). None of
these is reported to have a negative impact on cell prolif-
eration. Hence, it is unclear whether their reduced ploidy
plays any role in the transformation process. Notably, a 9-
fold increase in copy number of mitochondrial DNA was
observed for the cell line, likely reflecting the increased
energy demand of the actively dividing transformed cells
(Figure 2B). This finding is consistent with a previous
study [41].
We finally turned to an in-depth analysis of single nu-
cleotide (SNP) and insertion/deletion (indel) polymorph-
isms. Using an automated whole-genome comparison
algorithm (calldiff from cgatools) we found that 99.2% of
the variant calls were identical between the two genomes
(3,782,487 shared variants). Only 0.4% (15,364) and 0.3%
(11,435) of variants were unique to the genomic and the
cell line-derived DNA, respectively (Additional file 7,
panel B). Of note, this level of discrepancy is within
range of the error rate between technical replicates using
CGI technology (SY, unpublished observations). Al-
though the number of expected differences between the
2 genomes from the same individual was low a-priori,
we continued searching for potentially functional differ-
ences, namely non-synonymous variants such as “mis-
sense” (amino acid changing mutation), “nonsense”
(creating a stop codon where there was none before),
“nonstop” (removing an existing stop codon) or “frame-
shift” (changing the reading frame of a gene). For each
class of variant we identified the genes that were affected
in each sample and then determined the overlap be-
tween the two genomes. While we found that 92% of the
affected genes overlapped (5,995 genes total), these
genes were not always affected by exactly the same
mutations in both genomes. To test the reliability of
these called differences, we inspected the sequence reads
of 307 selected genes (exhibiting in total 647 non-
synonymous variants) using the Integrative Genomics
Viewer (IGV) [42]. We observed that in most instances
local coverage in one of the two genomes was very low,
thus no variation call could be made with high confi-
dence at that position. In other cases, one of the calls in
the two genomes was wrongly reported due to ambiguity
in the alignments (i.e. the reads could have been aligned
differently, so that the position of a variant differed be-
tween the genomes, even though the resulting non-
reference sequence was the same). Another common
discrepancy arose from the fact that a variant was deter-
mined to be homozygous in one of the genomes and
heterozygous in the other, even though both genomes
were homozygous (Figure 3A). Only 11% of the called



















































































































































Figure 1 Coverage of the two genomes. A: Number of reads is plotted against the number of bases for which that number of reads was
observed. The proportion of reads with a higher coverage (more reads) is slightly higher for the genomic DNA (black line) than for the cell line
(grey line). B: Proportions of the two genomes at a certain X coverage. C: Regional plot of averaged normalized coverages of the genomic DNA
(black line) and the cell line (grey line). The axes are spaced in increments of 10.
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visual inspection of actual reads (10 variants; Figure 3B),
implying that a considerable fraction of the reported dif-
ferences between genomic and cell line DNA represents
false positives.
In order to better control the false positive rate, we
used the option -SomaticOutput within calldiff, in which
a SomaticScore is computed for every variant that per-
mits adjusting for sensitivity and specificity (sensitivity =
1 - SomaticScore). The SomaticOutput analysis requires
specification of one sample as “normal” and another as
“tumor” and generates an output containing all loci that
are non-reference in the “tumor” sample. Since the
transformed cell line can be regarded as a tumor sample
derived from the normal genomic sample, definitions
were set accordingly (“Cell line - >Tumor (CT)” ana-
lysis). The reciprocal definitions were also analyzed as a
control (“Genomic - >Tumor (GT)” analysis). Since
most of the variants only found in the genomic DNA
sample are expected to be the result of sequencing or
calling errors, the GT analysis provides a reasonable esti-
mate of the experimental noise. For both comparisons,the number of variant calls was assessed using different
SomaticScore cut-off values. As shown in Figure 4A, in-
creasing the SomaticScore cut-off increased the propor-
tion of CT to GT variants, thus potentially maximizing
true positive findings. Even though the total number of
variant calls unique to the genomic DNA (retrieved by
the GT analysis) is larger (Figure 4B), a larger number of
variants was detected in the CT analysis at all tested cut-
off values (Figure 4A). To minimize false positives, we
chose a stringent cut-off of 0.5 [at this level, the number
of differences in the CT analysis (417) almost doubles
those found in the GT analysis (269)]. Assessing the re-
gional distribution of these mutations revealed that variants
unique to the cell line were randomly distributed through-
out the genome; in contrast, a high proportion of variants
unique to the genomic DNA seemed within or near telo-
meric or centromeric regions (Additional file 8). Interest-
ingly, 52% of variants in the CT analysis represented SNPs,
compared to only 6% identified in the GT analysis
(Figure 4B). Since SNPs are more reliably called than other
classes of variants, they are less likely to constitute noise.





























































































































































































Figure 2 Comparative display of structural variants of the two genomes. A: For the outer circle, the number of chromosomal
rearrangements was assessed in bins of 5 Mb for both the genomic (transparent blue) and cell line DNA (transparent red). In the inner circle
inter-chromosomal rearrangements are displayed. Because of the transparent colors, overlaps between the two genomes appear in purple. B: For
comparison, a similar visualization is shown as a smaller inset, plotting chromosomal rearrangements of the genomic DNA (blue) and the
genome of an unrelated individual (red). C: Genome ploidies for the genomic and cell line DNA are shown in the outer and inner circle,
respectively. The curve is colored in orange in genome stretches with a ploidy of smaller than 1, the area under the curve is filled blue when
ploidy exceeds 2. The axes are spaced in increments of 0.5.
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sent technical noise. We next compared the proportion of
SNPs that were novel (not present in the dbSNP database
[43]) in both analyses. Strikingly, whereas all SNPs that
were only present in the genomic DNA have been reported
before, none of the SNPs unique to the cell line were anno-
tated in dbSNP, with the exception of one variant
(Figure 4B). Although the low number of identified variants
between LCL and genomic DNA is within technical noise
their novelty suggests that, if real, most of these differences
would be random mutational events, driven by the acceler-
ated proliferation of transformed cells. When assessing
whether these SNPs altered coding sequences, we found
that while 40% of them overlapped with genes, none had
an impact on mRNA sequences. Specifically, except for one
SNP, all variants are either located in introns or untrans-
lated regions, thus their consequences are not straightfor-
ward (Additional file 9). None of the 15 SNPs unique to the
genomic DNA fell within a gene. In order to estimate the
exact error rate of this technology, we randomly selected 60
SNPs unique to the cell line and re-analyzed these by San-
ger sequencing. We could not confirm any of the identified
variants (data not shown), suggesting that the real number
of differences between the two genomes is even smaller
than that implied by the SomaticOutput analysis.Taken together, these results suggest that by using this
technology at 40X resolution DNA from the cell line is
mostly undistinguishable from genomic DNA from the
same individual. The few putatively true differences are ran-
domly distributed across the genome (Additional file 8) and
do not seem to drive the transformation process.
Discussion
Here we report on the first genome-wide sequence-
based analysis of the immediate genetic consequences of
EBV transformation on a low-passage lymphoblastoid
cell line from a subject with MS. While genomes from
MS and healthy individuals may differ slightly, we
deemed that this would not affect the conclusions of our
study, which focused on characterizing the genomic con-
sequences of EBV transformation. These effects should
be clear-cut and insensitive to the source of the sample
(with the exception of certain tumors, where DNA may
contain abundant somatic mutations). For decades, the
cell-transforming abilities of EBV have been used in gen-
etic research to create repositories of subjects’ DNA.
While the roles of viral gene products in the transform-
ation process have been described in detail, whether
genetic alterations are introduced as a consequence of
EBV transformation is less well understood.
AB
nonstop nonsense missense frameshift
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Figure 3 Most variant calls within genes are shared between genomic DNA and cell line. A: The Integrated Genomics Viewer (IGV) was
used to assess variants in genes that were affected by non-synonymous mutations in both genomes, but where the number or the position of
the variants differed. The following scenarios were encountered: (i) one of the calls in the two genomes was wrongly reported due to ambiguity
in the alignments (left panel), (ii) coverage in one of the two genomes was very low at the called position, thus no variant call could be made
(second left panel), (iii) a variant was determined homozygous in one of the genomes and heterozygous in the other, even though both
genomes were homozygous (second right panel, “false positives”) or (iv) the two genomes looked really different (right panel, “true positive”). All
reads were displayed in IGV. Each horizontal strip represents one read. Bases in agreement with the reference genome are displayed in grey,
non-according bases are colored. Insertions are depicted by a purple square, deletions by a thick line, and gaps by a thin line. At the top of each
panel, the relative coverage of each base in indicated by the height of the grey bar. The variant position is framed by two vertical lines. The
genomic DNA is shown in the upper part of the panel, the cell line underneath it, at the bottom the reference sequence is displayed. B: For each
class of non-synonymous variants (nonstop, nonsense, missense, frameshift), most mutations of this class in both genomic (blue) and cell line
DNA (red) are shared between the two genomes (purple). A high percentage of the mutations called to be unique to either of the two genomes
is not supported by actual reads.
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http://www.biomedcentral.com/1471-2164/13/477Several studies have systematically compared LCLs
directly to their parental cells using traditional molecular
techniques such as SNP typing, gene expression, and
whole chromosome analysis [12,44,45]. The overall con-
sensus is that no reproducible differences were identified
[7,45-47]. For instance, Redon et al. assessed differences
between DNA from HapMap LCLs and their genomic
counterparts and found that only 0.5% of observed
CNVs were caused by transformation [46]. Another
study confirmed that most CNVs in LCLs can also be
seen in normal B cells [47]. Two of the CNVs reported
in this latter study overlap with those detected in ourLCL. This is not surprising since the genomic DNA was
isolated from PBMCs, whereas the LCL is a B cell line –
hence B cell specific CNVs were identified as differences
to the genomic DNA in our study. The mitochondrial
DNA CNV reported here was also seen as a “cell line-
specific” CNV in a previous study [41].
Next generation sequencing was recently used to
compare genomic and LCL DNA, although only the
coding sequence (~1-2% of the genome) was assessed
in that study [33]. Specifically, authors used exome
sequencing to compare DNA from four LCLs with
their corresponding genomic DNA (extracted from













































Figure 4 Consequences of SomaticScore filtering in GT versus
CT analysis. A: Number of variants identified in GT (black bars) and
CT (grey bars) analyses passing a certain SomaticScore filter,
respectively. More variants meeting stringent filtering criteria are
identified in the CT analysis. In addition, the ratio of the number of
variants in CT to GT analysis is provided inside the graph. B: Some
characteristics of the variants identified in GT and CT analyses,
respectively. Even though a higher number of variants is found in
the GT analysis, a lower number passes the SomaticScore filter of
0.5, as compared to the CT analysis. Among these are only a few
SNPs (which are the most reliable called variants), all of which have
records in dbSNP. In contrast, all variants identified in the CT
analysis, represent SNPs and all of them, but one, have not been
reported before.
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analysis on SNPs and small indels, authors reported a
99.82% concordance between the parental DNA and
the cell lines, with all discordant calls stemming froma single LCL-donor pair [33]. Given the relevance of
non-coding regions in the modulation of gene expres-
sion and thus cell stability and function, whether the
high level of concordance between genomic and LCL
DNA extended to the whole genome remains an im-
portant question. By analyzing the whole genomes (at
40X) of an LCL and its genomic DNA counterpart,
we identified 9,468 and 12,719 unique variants with
respect to the reference genome, respectively. In-silico
analysis reduced the number of differences to 417
(216 SNPs, 201 indels) in the LCL and 269 (15 SNP,
254 indels) in the genomic DNA. However, none of
the 60 variants chosen for validation by Sanger se-
quencing were confirmed, thus suggesting that the
number of real differences ought to be significantly
smaller.
The known error rate of the ligation-based sequencing
technique we employed was empirically determined to be
approximately 1 in 100–200 kb (SY, unpublished observa-
tions). Hence, we can expect 20,000 to 30,000 errors in
each genome. In a previous comparison of two technical
replicate samples (sequencing the same sample twice) using
the same technology, 27,893 differences were detected (SY,
unpublished observations); we observed a similar number
of differences (22,187) between the genomic DNA and the
cell line genome in our analysis. These numbers highlight
how close the difference between the two genomes is to
technical noise. We therefore chose to minimize false posi-
tives in our analysis by applying stringent filters to the lists
of called differences. By these means we identified a num-
ber of SNPs that seemed enriched in the cell line (216 SNPs
in the CT analysis versus 15 SNPs in the GT analysis).
These variants represented silent mutations and appeared
to be random mutational events, possibly resulting from
the accelerated division rate of the transformed cells. How-
ever, we were not able to confirm a selected subset of those
SNPs and further validation is needed to establish any true
discrepancies between the genomic DNA and the cell line.
Conclusion
In conclusion, our results indicate that EBV transformed
cell lines at low passage number/short time in culture
are genetically indistinguishable to the parental cells,
suggesting that discoveries in genetic studies conducted
using low-passage LCLs with a normal karyotype can be
extrapolated to the parental patient samples. We deter-
mined with high confidence that 99.2% of the genomes
were identical, with no reproducible changes in struc-
tural variation (chromosomal rearrangements and CNV)
or indels. While we identified 231 differences (216 from
the LCL, 15 from the genomic DNA) in single nucleo-
tide variants, none of the 60 randomly selected variants
validated by Sanger sequencing. These findings suggest
that the true differences between the two genomes ought
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informatics filters (proportions test; 95% confidence
interval p-value: 1.3 x 10-14). We acknowledge that the
sample size is a limiting factor of this study, and while
similar results were reported by independent groups
using different technologies [7,9,33,45-47], larger studies
will be needed to precisely determine the genomic
effects of EBV transformation.
Methods
Sample preparation
A lymphoblastoid cell line was established from whole
blood from an adult male suffering from multiple scler-
osis, essentially as described in [48] (a detailed protocol
can be found in Additional file 10). Briefly, a buffy coat
was obtained from freshly drawn blood and PBMCs
were cultured with EBV supernatant. After infection,
cells were kept in culture for 6 weeks. DNA was then
extracted using standard salting-out procedure. DNA
concentration was determined using the picogreen assay
and adjusted to 0.1 μg/μl. DNA quality was assessed on
an agarose gel prior to sequencing (Additional file 11).
15 μg DNA were sent for sequencing. The study was
approved by the Institutional Review Board at the Uni-
versity of California San Francisco (UCSF).
Sequencing
Genomes were sequenced and aligned by Complete
Genomics Inc. (Mountain View, CA) (CGI, details on
the technique in [34]). Sequence reads were aligned to
genome release hg19 and all annotations were per-
formed based on this genome release. CGI provided 6
data files (evidence, variants, gene variant summary,
gene, CNV segments, and high-confidence junction files)
that were used in the analysis (software version
1.10.0.22, format version 1.5; Additional file 7 panel A),
most importantly the evidence and the variance files list-
ing all sequenced loci that deviate from the reference
genome. A position is either classified – or called – as
“reference”, when the reads conform to the reference
genome, or as “variant” if they do not accord. If a variant
was called in this first round, corresponding reads are
newly assembled to accurately determine the sequence
of the variant locus; the resulting information is stored
in the evidence file (assembled reads) and variance file
(variant calls). Variants are classified into different
classes, including SNP, deletion, insertion or substitu-
tion. All variants are assigned a score expressing the
confidence of the variant call [this score was not used to
prioritize variants for analysis; however, this score is
incorporated into the SomaticScore (see below)]. Two
other files, the gene variance summary file and the gene
file, list all genes that are affected by a variant; the latter
gives all variant positions that fall into genes, includinguntranslated regions, splice sites and introns, whereas
the gene variance file specifies the number of mutations
that can either be classified as “missense” (amino acid
changing mutation), “nonsense” (creating a stop codon
where there was none before), “nonstop” (removing a
stop codon), “frameshift” (changing the reading frame of
a gene) or “inframe”. Finally, the CNV segments file con-
tains relative coverage and ploidy calls in windows of
2 kb, while the high-confidence junction file provides in-
formation on putative chromosomal rearrangement
events. Genome data has been deposited at the Euro-
pean Genome-phenome Archive (EGA,http://www.ebi.
ac.uk/ega/) which is hosted at the EBI under accession
number EGAS00001000323.Genome analysis
Analysis of variant calls
The variant files of the two genomes were compared to
each other using the function calldiff from cgatools 1.3.0
package [49]. An overview of overall differences was out-
put by choosing the reports argument “SuperlocusStats”.
For in-depth analysis of differences, the somatic output
report was used (reports argument “SomaticOutput”).
For this report, a “normal” and a “tumor” sample has to
be specified. The tumor sample will be compared only
to reference loci in the normal sample and the output
will contain all non-reference loci in the tumor sample.
Each call is assigned a “SomaticScore”, which indicates
the reliability of the call. By using a SomaticScore of x, a
sensitivity of 1-x is achieved. Being aware that the num-
ber of differences we observed was within the expected
noise range, we chose a high SomaticScore of 0.5, know-
ingly losing some true positives, but minimizing false
positives. From the resulting list of variants all loci that
were not fully called were excluded. We did two analysis
runs: (1) CT analysis (i.e. cell line is the tumor sample);
(2) GT analysis, (i.e. genomic DNA is the tumor sample)
as a comparison. Variants were mapped to genes using
the CGI gene files.Analysis of CNV calls
CNV calls were visually inspected by plotting the relative
coverage of each genome using the Circos software [50].
For an in-depth analysis, the presence of calls reported
in one genome, the “reference”, was assessed in the
other genome, taking both cell line and genomic DNA
as reference. For this search, only calls with a ploidy-
Score greater than 40 in the reference were considered.
The start and end points of the CNV call are not
required to be an exact match, but have to fall within a
2 kb window around the start and end points in the
reference. For each CNV call present in both genomes,
ploidy calls were compared. When these differed
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genomes and visually assessed.
Analysis of chromosomal rearrangements
CGI provides a high confidence junction file for each
sequenced genome, which lists events of discordant read
pairs within a given DNA nanoball (DNB). In this file,
sequences that are not adjacent in the reference genome
are reported; these are defined as “junctions”, consisting
of a “left arm” reference sequence, a breakpoint with an
optional transition sequence (a stretch of sequence that
is not contained in the reference genome) and a “right
arm” reference sequence at a non-adjacent genome loca-
tion. CGI also reports the frequency with which each
identified junction was found in previously sequenced
genomes (the higher the frequency, the more likely the
reported junction might be an artifact of the sequencing
technology). For the graphical (e.g. Circos) analysis, all
high confidence junctions seen in 75% or more of CGI
sequence data sets were removed. For visually contrast-
ing structural variance calls of the two genomes, only
inter-chromosomal high confidence junctions (as deter-
mined by CGI) were plotted. In addition, the total num-
ber of junctions in bins of 5 Mb was calculated with the
help of the software tool binlinks that is distributed to-
gether with Circos. In-depth analysis was performed by
comparing CGI’s high confidence junctions files for the
different genomes using cgatools 1.3.0 junctiondiff [49].
The program was run using the standard settings, i.e.
the scoreThresholdA was set at 10, scoreThresholdB at
0, the maximum distance between the coordinates of the
putatively compatible junctions at 200 and the minimum
deletion length at 500. CGI provided accession numbers
of genes that were affected by chromosomal rearrange-
ments. Accession numbers affected by junctions specific
to one of the genomes were translated into geneIDs and
symbols using the Bioconductor/R package “biomaRt”
[51]. Then, enrichment for GO and KEGG categories
was assessed using the “GOstats” R package [52].
Analysis of non-synonymous variants
For each class of non-synonymous variant - “missense”,
“nonsense”, “nonstop” or “frameshift” -, all genes with at
least one mutation in genomic and cell line DNA were
determined, respectively. Of all genes that were affected
by the same class of mutation in both genomes, mutations
were compared between genomic and cell line DNA. If
position or type of the variant was not identical in the two
genomes, raw sequence reads were displayed using the In-
tegrative Genomics Viewer [42] and visually compared.
Detection of viral DNA
To assess the presence of viral DNA sequences within
the whole genome data sets, all reads that could not bemapped to the human genome were extracted. Next, the
reference genome sequence of EBV was downloaded in
fasta format from the NCBI. Then, unmapped reads
were aligned to this reference genome using bwa [53].
Subsequently, samtools [54] was used to convert aligned
reads into bam format to enable display in IGV and cal-
culate EBV genome coverage (44X). In addition, we
extracted all transition sequences (sequences that join
the two arms of chromosomal junctions, but are not
present in the reference genome) as well as reported
insertions and longer than 8 nucleotides from the junc-
tions that were unique to the cell line and blasted them
against the EBV genome (using NCBI BLAST).Karyotyping and Sanger sequencing
Karyotyping was performed by the Cytogenetics Labora-
tory of UCSF. Sanger Sequencing was performed by the
Genomics Core Facility of UCSF. Sequencing primers
were designed based on a 200 bp region flanking the
SNP that was inquired. 60 randomly selected discordant
SNPs were sequenced using two independent primer
pairs per position.Additional files
Additional file 1: High resolution karyotype of cell line. The cell line
exhibits a normal karyotype.
Additional file 2: Comparison with previously published whole
exome/genome datasets. Comparison of a number of sequencing
characteristics with previously published genomes/exomes.
Additional file 3: Number of chromosomal rearrangements in both
genomes. Information on all high confidence junctions identified per
genome and the number of unique junctions, specifying the number of
junctions with a frequency of less than or equal to 75% (i.e. seen in less
than or exactly 75% of all genomes sequenced by CGI at the time) and
the percentage of inter-chromosomal rearrangements.
Additional file 4: Chromosomal rearrangements that were only
reported for the genomic DNA sample. This file contains details on
the chromosomal rearrangements (junctions) unique to the genomic
DNA sample.
Additional file 5: Chromosomal rearrangements that were only
reported for the cell line sample. This file contains details on the
chromosomal rearrangements (junctions) unique to the cell line sample.
Additional file 6: Copy number variation (CNV) differences between
genomic and cell line DNA. Copy number variation (CNV) differences
between genomic and cell line DNA.
Additional file 7: Analysis strategy and overall differences found
between the two sequenced genomes. A. Workflow of the genome
analysis. Besides various data files and software tools provided by
Complete Genomics (blue), Bioconductor packages and R (green) were
used for analysis. B. Gross comparison statistics as output from cgatools
calldiff SuperlocusStats. “Identical” sequences are sequences that are fully
called and identical in both genomes. “Consistent” sequences are not
fully called, but what is called is identical in both genomes. “Only C” and
“Only G” denote variants only found in cell line and genomic DNA,
respectively. At “mismatch” positions, the two genomes are different from
each other and different from the reference. “Phase-mismatch” means
that even though the two genomes have the same alleles, the phase of
the alleles differ. The two genomes don’t have any “ploidy mismatches”
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Y chromosome).
Additional file 8: Distribution of filtered variants across the
genome. All variants passing a SomaticScore cut-off of 0.5 in the CT
(outer circle) and GT analysis (inner circle) are plotted, respectively. SNPs
are displayed in orange, insertions in blue, substitutions in green and
deletion in yellow.
Additional file 9: Filtered SNPs unique to the cell line targeting
gene loci containing a coding sequence. Filtered SNPs unique to the
cell line targeting gene loci containing a coding sequence.
Additional file 10: Protocol for the creation of lymphoblastoid cell
line. The detailed protocol that was used to create the lymphoblastoid
cell line that was studied.
Additional file 11: Quality of the DNA sent for sequencing. 400 ng
of DNA were loaded per lane on a 1% agarose gel. Marker: 1 kB DNA
ladder (New England Biolabs, Ipswich, MA). No DNA degradation was
detectable. Samples were run on the same gel, but on opposite sides.Competing interests
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